FDA gives tentative approval to Teva's abacavir sulfate, lamivudine tabs

SILVER SPRING, Md. — The Food and Drug Administration has granted tentative approval to Teva Pharmaceutical for abacavir sulfate and lamivudine tablets in 600-mg and 300 mg strengths, according to agency records. 



Abacavir sulfate and lamivudine combination tablets is used for the treatment of HIV-1 infection.